CN Patent

CN116726035A — 用于包括线粒体dna耗竭综合症在内的由不平衡的核苷酸库引起的疾病的脱氧核苷疗法

Assigned to Fund Hospital University Vall D'hebron Institut De Recerca · Expires 2023-09-12 · 3y expired

What this patent protects

本发明通常涉及人类遗传疾病的药理学疗法，所述人类遗传疾病具体地是以不平衡的核苷酸库为特征的那些，更具体地是线粒体DNA耗竭综合症，且更具体地是胸苷激酶2(TK2)缺乏症。所述药理学疗法涉及施用至少一种脱氧核苷或其混合物。对于治疗TK2缺乏症，所述药理学疗法涉及施用脱氧胸苷(dT)或脱氧胞苷(dC)或其混合物。脱氧核苷的这种施用适用于不平衡的核苷酸库的其它病症，特别是见于线粒体DNA耗竭综合症的那些。

USPTO Abstract

本发明通常涉及人类遗传疾病的药理学疗法，所述人类遗传疾病具体地是以不平衡的核苷酸库为特征的那些，更具体地是线粒体DNA耗竭综合症，且更具体地是胸苷激酶2(TK2)缺乏症。所述药理学疗法涉及施用至少一种脱氧核苷或其混合物。对于治疗TK2缺乏症，所述药理学疗法涉及施用脱氧胸苷(dT)或脱氧胞苷(dC)或其混合物。脱氧核苷的这种施用适用于不平衡的核苷酸库的其它病症，特别是见于线粒体DNA耗竭综合症的那些。

Drugs covered by this patent

Patent Metadata

Patent number
CN116726035A
Jurisdiction
CN
Classification
—
Expires
2023-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Fund Hospital University Vall D'hebron Institut De Recerca
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.